

2022 Glenn A. Fry Award Lecture: Enhancing Clinical Assessment for Improved Ophthalmic Management

James S Wolffsohn BSc, MBA, PhD, FAAO, Diplomate CCLRT

School of Optometry, College of Life and Health Sciences, Aston University, Birmingham, UK

Abstract

Detailed clinical assessment is critical to allow sensitive evaluation of the eye and its management. As technology advances, these assessment techniques can be adapted and refined to improve the detection of pathological changes of ocular tissue and their impact on visual function. Enhancements in optical medical devices including spectacles, contact and intraocular lenses, have allowed for a better understanding of the mechanism and amelioration of presbyopia and myopia control. Advancements in imaging technology have enabled improved quantification of the tear film and ocular surface, informing diagnosis and treatment strategies. Miniaturized electronics, large processing power and in-built sensors in smartphones and tablets capacitate more portable assessment tools for clinicians and facilitate self-monitoring, treatment compliance and aid communication with patients. This article gives an overview of how technology has been used in many areas of eye care to improve assessments and treatment, as well as providing a snapshot of some of my studies validating and utilising technology to inform better evidence-based patient management.

We live in an amazing world. In most cases, scientists have learnt that trying to mimic 'nature' is the most efficient approach to enhance human innovations. Every time we peel back a layer of biological complexity through human ingenuity, more research questions are generated and more of nature's beautiful architecture is revealed. This architecture is not fixed, but adapts with its environment. It is inconceivable to me that this is the result of a random, uncreated universe, or just one of infinite universes which just happens to be able to sustain life as we know it and in which we have the good fortune to exist. My belief in a created, structured universe is what has motivated my career to develop instrumentation and techniques to better understand the workings of the eye as it interacts with medical devices (such as contact lenses and intraocular lenses) and the changing environment (such as impacting dry eyes, ocular allergy and myopia; Figure 1). As a clinical scientist, my ultimate goal is to achieve impact by translating research into evidence-based clinical practice, by collaboration and challenge to create change (such as through consensus reports and practice surveys) for the benefit of patients, who are my inspiration for research ideas.




Figure 1: Summary of the research covered in this paper.

Instrumentation

It is critical for clinicians and researchers to understand the instrumentation they use in the clinic (not just how to take a measurement) and that it is optimised for its purpose.^{1,2} The same is true for measurement techniques, where repeatability and standardisation are key for successful treatment.

Assessment of Functional Vision, Eye Focus / Accommodation

Visual acuity is a well-established metric of visual function,³ but while the measurement procedure is well defined for distance,⁴ clinical measurement parameters for intermediate and near distances have been more variable. The logMAR spacing of letters and lines to unify the visual demand at all levels of acuity should be adopted,⁵ but there is a choice whether the chart is more functional using words of defined length and difficulty⁶⁻⁸ or capital letters to standardized with distance acuity measurement.⁹ The more physical method of measuring visual acuity at a range of distances used in the past¹⁰⁻¹² is often impractical owing to the need to control angular image size and luminance. Rather than discrete distances, the accommodative demand can be altered with lenses,^{13, 14} and we have shown that optimally these should be presented in a randomised order^{15, 16} in 0.5D steps¹⁷ and correcting for image minification/magnification,¹⁶ to plot a defocus (or through focus) curve to map the expected acuity of an individual over the functional range of distances from far to near. The subjective range of focus has been extracted from the resulting acuity defocus chart by various absolute and relative approaches,¹⁶ but we have proposed reporting the area under the curve in discrete distance ranges, to ensure more standardised comparisons can be made.¹⁸

When I started my PhD, we used an already discontinued open-field (to minimise instrument myopia)^{19, 20} autorefractor, the Canon R-1,²¹ to measure objective accommodation (changes in eye focus) by subtracting the refractive error on distance viewing from that when observing a high contrast target at near. The opportunity arose on moving back to the UK to validate a new open-field commercial autorefractor²¹⁻²⁶ and later to build the first truly open-field aberrometer²⁷ to further this research. Originally it was proposed that accommodation might be underestimated if the target was closer than an individual's subjective range of clear focus²⁸, however we have since shown that

individuals are able to sustain their maximum accommodation even if the accommodative demand of the target is greater than this and as a result, appears blurred²⁹. The accommodative system is remarkably robust to fatigue³⁰ and we have demonstrated that much of the accommodative range can be utilised even for prolonged demanding tasks,³¹ although there is a lag of accommodation³² with no more accommodation exerted under normal circumstances than needed to keep the target clear.³³

The dynamics of accommodation can also be measured dynamically and we were able to adapt commercial autorefractors^{23, 34-39} and subsequently our open-field aberrometer²⁷ for this purpose; with these techniques we were able to show ciliary muscle driven 'accommodative' restoration in early accommodating intraocular lenses designs, although this was of low magnitude and was only maintained for a limited time due to fibrosis post cataract surgery,⁴⁰⁻⁴² with some lenses extending the range of clear focus mainly through aberration changes.⁴³ Ex-vivo, these novel accommodating intraocular lens prototypes can be tested and refined through attaching them to mechanical lens stretchers⁴⁴⁻⁴⁶ with us recently developing a synthetic lens capsule they can be 'implanted' in.^{47, 48}

High contrast, static visual acuity is an important safety metric,⁴⁹ but is not a good predictor of functional vision.⁵⁰ Most near tasks involve an element of reading,⁵¹ which is perceived as being critical to communication and commerce in modern societies.⁵² Reading speed is fairly consistent until the critical text size is reached, after which it rapidly slows until the near acuity threshold.^{50, 53} As a consequence, an acuity reserve has been shown to be needed to optimise reading performance.⁵⁴⁻⁵⁶ Reading speed charts were originally paper based,⁵⁷⁻⁵⁹ with an individual manually timed reading aloud paragraphs of text, and then the times had to be time-consumingly plotted to extract the 'reading speed' metrics.⁶⁰ Working with engineering colleagues we digitised this process on a tablet (Figure 2)⁶¹ which allowed us to use the onboard sensors for the additional benefit of working distance and gaze monitoring, blink analysis, voice recording to allow for incorrect syllable detection and immediate data analysis.⁶² We used a similar digital device clinical test approach

(Figure 2) to assess the adverse effects of presbyopia corrections in the form of multifocal optics. Conventional contrast sensitivity tests measure contrast detection at one spatial frequency⁶³, or spatial frequency at two to nine contrasts^{64, 65} it is now possible to display the contrast sensitivity function as a sine wave grating with varying contrast (Y-axis) and spatial frequency (X-axis) as Robson and Campbell originally portrayed⁶⁶ on a tablet screen, with the user tracing their finger where they can see the tops of the maxima (Figure 2) which we utilised to create and validate an app to generate a complete contrast sensitivity function in under a minute;⁶⁷ this is despite a study suggesting that the generated curve was not accurate, but instead of tracing the curve, they fitted their own simulation of the sinusoidal function with only 4 points.⁶⁸ Likewise, glare is traditionally assessed through basic reporting,^{69, 70} a questionnaire,^{71, 72} assessing its impact on an acuity/contrast task (Figure 2)⁷³⁻⁷⁵ or by getting an individual to sketch the extent to which a bright light appears to scatter.⁷⁶⁻⁷⁸ however, we developed a more objective approach where the glare profile of an individual can be plotted as the area obscured by a glare source, by moving targets out from behind it in multiple directions, with the patient reporting the position (eccentricity) when it can first be reliably detected (Figure 2).⁷⁹⁻⁸¹




Figure 2: Tablet based visual function assessment applications.

While it has been possible to improve the sensitivity, reliability and clinical application of a range of traditional and newer visual metrics, these do not fully capture the patient experience. Patient reported outcome measures take input from multiple patients with the disease of interest and clinical experts, applying statistical optimization (such as Rasch analysis) to develop,⁸² but allow quality of life in conditions to be assessed. We have been involved in developing quality of life questionnaires for macular degeneration,^{83, 84} visual impairment⁸⁵⁻⁹⁰ and presbyopia.⁹¹⁻⁹³ With time

we have had to develop some further to remain relevant to changing lifestyles and impact of social media,^{94,95} especially the ubiquitous digital environment.^{96,97} We have demonstrated they are influenced by whether they are self-completed or the questions are posed to them, so this needs to remain the same if scores are to be compared over time or across patients / treatments.⁹⁸ Traditional patient reported outcome measures only assess one trait, by design, so do not account for the patient experience of the management of their condition. Hence patient reported experience measures^{99,100} and item-banks¹⁰¹ are needed in future to better monitor the impact of ocular disease and management approaches.

Enhancing Residual Vision in the Visually Impaired

Visual impairment from ocular disease is generally un-correctable, so low vision rehabilitation focuses on making the best use of the remaining vision¹⁰²⁻¹⁰⁵ such as through the use of coloured lenses,¹⁰⁶⁻¹⁰⁸ optical magnifiers^{109,110} (including optimised page illumination)¹¹¹ and electronic vision enhancement systems (EVES)¹¹²⁻¹¹⁴ which we and other research groups have evaluated. We developed the terminology EVES to better describe the use of technology that has emerged in instrumentation for those with low vision than the traditionally used Closed Circuit Television (CCTV) terminology. EVES can allow real-time digital enhancement of text¹¹⁵ and we have demonstrated it benefit in television¹¹⁶ or even real-world viewing through a head-mounted helmet¹¹⁷⁻¹¹⁹. Clinicians need to balance the desire for greater magnification,¹²⁰ with the compromise of a smaller field-of view and an increasing scanning requirement.¹²¹

Monitoring Ocular Physiology

Subjective grading scales vastly improved practitioner attempts to describe clinical features such as ocular redness,^{122,123} which are impacted by changes in ocular physiology such as with disease

severity or product toxicity.¹²⁴ Research by us and other research groups have demonstrated that clinicians use both the area and redness of the vessels to make their clinic judgement of severity.^{125, 126} However, we have shown that anterior eye grading scales are not comparable or that linear,¹²⁷ breaking a continuous physiological variable into a limited number of discrete steps,¹²⁸ while it was initially advocated that 0.1 increments would increase the sensitivity of grading,¹²⁹ we found 0.5 increments within the usual 4 to 5 point scale seems to be the best that can be differentiated by clinicians¹³⁰. With digital imaging, we have extracted and objectively quantified features associated with ocular physiology such as redness^{126, 131} and transparency,¹³² from images of sufficient resolution / compression format,¹³³ improving sensitivity and repeatability of assessment.¹³⁴ These can be translated back to typical clinical scale grades to aid clinical interpretation.¹³¹ Others have applied similar techniques to staining¹³⁵⁻¹³⁷ and gland drop-out.^{138, 139}

Tear film biomarkers have been linked to systemic as well as ocular disease.¹⁴⁰⁻¹⁴² Hence the possibility of non-invasive extraction of tear film biomarkers that can be analysed in a clinical setting (point of care) using 'lab-on-a-chip' technology is an attractive proposition that we and others have utilised.¹⁴³⁻¹⁴⁶ The sampling of tears is still a challenge with capillary tube,¹⁴⁷ sponge,¹⁴⁸ Schirmer strip^{147, 149} and eye wash^{150, 151} techniques, each having their own profile of lipid and protein capture. Even within a technique such as using a Schirmer strip, we have shown there is significant variability between brands.¹⁴⁹

The slit lamp biomicroscope consists of magnifying binoculars and a conjugate illumination system that can be varied in spectral transmission, height and width.^{2, 152, 153} Together with its stabilisation of the patient on a chin and head rest and adjustable three-directional stage, it has become a core instrument for the examination of both the anterior and posterior eye. Fluorescein dye is widely used to assess corneal compromise and damage,^{154, 155} but with careful tuning of the blue illumination (with a peak at 495nm, not Cobalt infused glass with its peak around 450nm!) and yellow observation filter (with a sharp cut-off at 500nm), we demonstrated the image is much

enhanced.¹⁵⁶ Specific instruments have been developed from the early corneal topographers using light to enhance anterior eye images, with Placido discs¹⁵⁷ to view the stability of the tear film over time,¹⁵⁸ cool white light to visualise the lipid layer through interferometry,¹⁵⁹ blue light to excite fluorescein dye molecules to assess corneal damage¹⁵⁶ and infrared light to perform meibography,¹⁶⁰ although our research has identified these instruments are not always initially optimised.¹⁶¹

Impact of Technological Advances in the Optics and Properties of Ophthalmic Medical Devices

Many ophthalmic medical devices have been developed to overcome refractive errors, with more complex optics applied to the amelioration of presbyopia,^{162, 163} which our seminal position paper defined as “when the physiologically normal age-related reduction in the eyes focusing range reaches a point, when optimally corrected for distance vision, that the clarity and comfort of vision at near is insufficient to satisfy an individual’s requirements”.¹⁶⁴ They can be implanted (such as intraocular lenses)¹⁶⁵ or applied to the ocular surface (such as contact lenses)¹⁶³ and need to have minimal impact on the physiology of the eye.

Our advancements in the understanding of contact lenses, particularly to reduce the drop out¹⁶⁶ linked with prior ocular surface disease,¹⁶⁷⁻¹⁷⁰ have included better evaluation of lens fit,¹⁷¹⁻¹⁷⁷ the emergence of silicone hydrogel materials¹⁷⁸⁻¹⁸³ along with their impact on ocular surface temperature^{184, 185} and corneal oxygen consumption,¹⁸⁶ lubricating solution delivery¹⁸⁷⁻¹⁸⁹ and nano-thickness surface coatings (to change surface lubricity while maintaining lens material bulk properties).^{190, 191} Our translational research on soft contact lens fit evaluation has led to a simplified recording method where centration/coverage, movement on blink on up-gaze, lag on horizontal gaze and push-up recovery speed are graded on a three point scale¹⁷⁴ to inform clinical decision making,¹⁷² which has been adopted by the International Association of Contact lens Educators (IACLE). We have also provided similar practical guidance on rigid corneal lens evaluation.^{175, 192}

Advances in instrumentation have allowed us to better understand of how soft contact lenses drape over the cornea and sclera (which is more of a tangent than previously thought),¹⁹³⁻¹⁹⁷ the shape profile of contact lenses¹⁹⁸ and the impact of lens design on its centration and mobility.^{173, 199, 200} We developed a technique to compensate for image distortion due to the optics of the eye,²⁰¹ which had previously been overlooked, leading to the incorrect observation²⁰² that soft contact lenses significantly indent (build up) the corneal epithelium.^{199, 203}

For contact lens wearers, we have shown toric surfaces can improve the visual function of astigmatism²⁰⁴⁻²⁰⁸ and multifocal optics can assist in ameliorating presbyopia,^{50, 183, 209} although it is challenging to predict the benefits of different designs for an individual patient, as we and others have shown.^{210, 211} We demonstrated multifocal contact lens use is often one of a number of correction options used by an individual for different life environments,²¹² in a similar way as to them not restricting themselves to one set of clothes or pair of shoes for all occasions. Daily disposable soft contact lenses can also be a useful barrier for airborne antigens in our controlled environment,²¹³ similar to that found in lens wearers.²¹⁴ In addition, we have evaluated their ultraviolet radiation filtration,²¹⁵⁻²¹⁷ protecting the crystalline lens from a loss of flexibility.²¹⁸ Scleral lenses can stabilise a protective fluid layer on the ocular surface²¹⁹ and we have revealed they have little impact on corneal physiology in daily wear if the lens Dk/t is at least 125.²²⁰⁻²²²

I have played a mentoring role to support academics in the British and Irish, University and Colleges Committee of Contact lens Educators (BUCCLE) to review the evidence-base for key areas of clinical contact lens practice^{124, 223} and conducted studies to address gaps such as the adaptation time required after fitting neophytes^{224, 225} (which has now been replicated by another group)²²⁶ and optimising the grading of ocular physiology.¹³⁰ To consolidate the increasing evidence-base in contact lenses, I brought together experts in the field to create the Contact Lens Evidence-based Academic Reports (CLEAR), published in 2023; this was an initiative to support clinicians in performing evidence-based practice to the benefit of their patients, to identify gaps in the literature

for researchers to tackle and to identify opportunities for industry to innovate²²⁷⁻²³³. These advocate for changes to commonly used, but unhelpful, terminology such as: referring to ‘corneal rigid lenses’ rather than rigid gas permeable (which would include scleral lenses)²³⁴ or gas permeable (which described all modern) contact lenses;²²⁸ avoiding the overlap between continuous and extended wear definitions^{235, 236} by using ‘planned’ or ‘sporadic’ ‘overnight wear’ which fit better with the risk of complications;²³⁷ and replacing eponym terms (named after an individual) with the Federative Committee for Anatomical Terminology²³⁸ recommended ‘anterior limiting lamellar’ rather than Bowman’s layer and ‘posterior limiting lamellar’ to replace Descemet’s membrane.²³⁹

We have reported how intraocular lenses have developed rapidly over the past two decades^{240, 241} with our research identifying improvements in toric lens stability²⁴²⁻²⁴⁶ (and improving on the objective assessment of lens rotation and centration)²⁴⁷ and evaluating more advanced multifocal optics²⁴⁸ such as segmented,^{80, 249} trifocal^{69, 81} and those that aim to simulate true ‘accommodating’.⁴⁰⁻⁴³

Myopia Control

Early research exploring the increase in myopia globally was focused on the impact of near vision on the oculomotor system,²⁵⁰⁻²⁵² such as our research on near work-induced transient myopia^{253, 254} and changes in autonomic stimulation.^{33, 255, 256} However, since the advent of treatments which can reduce the amount of myopia a child will develop (i.e. myopia control rather than management),²⁵⁷⁻²⁵⁹ unlike approaches such as undercorrection,^{260, 261} we have charted a growing concern amongst practitioners across the globe and uptake of myopia control treatments.²⁶²⁻²⁶⁶ Advances in biometers, such as the ones we have validated,^{267, 268} have allowed eye growth to be more sensitively tracked and longitudinal data on untreated children²⁶⁹⁻²⁷² is being used in our app to allow practitioners to share a child’s eye growth curve prediction to be shared with their parents along with tracking real world data on myopic control appliances and approaches (Figure 3). Through

being appointed the International Myopia Institute Chief Scientific officer, white papers have been published on a range of key aspects of evidence-based myopia understanding such as best practice for designing clinical trials,²⁷³ the role of binocular vision,²⁷⁴ public health initiatives,^{275, 276} clinical guidelines^{277, 278} and digests updating previous white papers.²⁷⁹⁻²⁸¹



Figure 3: Myopia prediction and monitoring app for practitioners and MyDryEye symptom monitoring and treatment tracking app for patient examples.

Technology Driven Enhancements in Ocular Surface Disease Diagnosis and Treatment

The Tear Film and Ocular Surface Society defined dry eye as “a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles”.²⁸² It is a disease of both symptoms and signs, so it is a subset of ocular surface disease. It was acknowledged as a disease, rather than a condition, due to its impact on individuals lives, impacting quality of life, livelihoods²⁸³⁻²⁸⁵ and mental health.²⁸⁶⁻²⁸⁸ Its prevalence has been reported to vary widely across different populations,²⁸⁹ but some of the variation is likely due to the previous lack of an accepted diagnostic criteria. A number of symptomology questionnaires have been developed to ‘diagnose’ dry eye,²⁹⁰ but each of them has limitations in how they were designed and evaluated compared to current standards.^{291, 292} By refining the most common questionnaire, the Ocular Surface Disease Index (OSDI) with its 12 items, allowed us to reduce it to six of its original questions, without losing sensitivity and specificity, while reducing the response burden.²⁹³

Placido disc topographers have been converted from static image capture to video outputs,^{161, 294} allowing the stability of the tear film (which is the where the change in refractive index occurs to give the mire reflection) to be assessed²⁹⁵ as well as to apply software tools such as to quantify the tear meniscus height²⁹⁶⁻²⁹⁸ or to assess meibomian gland drop-out.^{138, 139} In addition, blue (to assess fluorescein staining)¹⁵⁶ and infrared (to allow visualisation of the meibomian glands after lid everting)²⁹⁹ light modes are usually available.³⁰⁰ Apps are being developed to allow some of these measures (such as symptomology,³⁰¹ functional dynamic visual acuity³⁰² and tear meniscus height imaging)³⁰³ to be conducted on widely available smartphones; this is an area where more technological innovation is expected in the near future, including the use of artificial intelligence to quantify physiological change.^{139, 304} For example, we developed a simple digital test that can be presented on a smartphone (Figure 3), in which individuals simply reported how many seconds after

a blink their eyes felt uncomfortable, in combination with a standard questionnaire, achieved a 71% sensitivity and 90% specificity of a full TFOS DEWS II diagnosis of dry eye disease.³⁰⁵

Risk factors of dry eye disease are fairly consistent across the world including female sex, menopause, limited sleep, digital device use and contact lens wear.^{289, 306-311} Most worrying is the increase in ocular surface disease in children,^{312, 313} such as our finding of a correlation between digital screen time and meibomian gland loss³¹⁴. Digital eye strain (symptoms resulting from digital device use) is common across a range of ages^{315, 316} and a recent TFOS Lifestyle report that I chaired³¹⁷ consolidated the evidence on risk factors, the mechanism (largely driven by the reduction in complete blinking) and management (with omega-3 supplementation being the only approach with strong evidence of a beneficial effect). Optimisation of the ocular surface, binocular vision and refractive error correction are all key to reducing digital eye strain, and there is growing evidence for the importance of regular breaks (such as advocated by the 20/20/20 rule which now has some evidence behind from us and another research group,^{318, 319} but this advice might not yet be optimised)³²⁰ and blink exercises.³²¹

While dry eye disease is still subclassified into evaporative and aqueous deficiency components, there is much variability as to how these are defined in a research setting, our research findings suggest that there are probably more subtypes within this multifactorial disease.³²² We have shown that examination of the meibomian glands can inform the likely improvements with eyelid debridement and warm compresses.³²³ Consistent lid eversion with a robust technique (as we have evaluated)³²⁴ is critical to meibography, with some papers reporting regeneration of the glands³²⁵ which seems unlikely over the short time periods and with the interventions reported.

Artificial tears are the mainstay of dry eye disease management.³²⁶⁻³²⁹ In a longitudinal study designed to provide an evidence-based guide to the use of artificial tears for those with dry eye disease, we found symptoms will improve within a month in those they benefit (approximately two-thirds of those in the trial), with signs taking up to 6 months to be impacted from four times a day

prescribed usage.³³⁰ Hence the importance of ongoing use of artificial tears should be emphasised, but if there is no improvement in symptoms by a month of compliant use, another approach should be tried. Those that have the evaporative dry eye subtype gain more benefit from artificial tears including lipids, as we have found previously.^{330, 331} Lipid sprays are effective despite being sprayed on the closed eyelid, rather than directly onto the ocular surface,³³² although this does depend on the formulation.³³³ These findings provide the evidence which informs our current management of patients with dry eye disease (Figure 4). Tear film biomarkers³³⁴⁻³³⁶ and advanced corneal imaging³³⁷ to personalise dry eye disease management and point-of-care devices to quantify them^{143, 144, 338, 339} are an area of active research by our group and others.

Other simple treatments for dry eye disease include warming the meibomian glands. Microwave heated compresses work well^{340, 341} and are better than the traditionally advocated water warmed flannels^{342, 343} as they maintain the required temperature³⁴⁴ of around 40°C³⁴⁵; however, there is still scope to refine the treatment protocol and to assess whether mechanical in-office³⁴⁶⁻³⁴⁸ or portable devices we have evaluated³⁴⁹ outperform simple approaches. We have shown that the meibomian glands do need to be more than 10% of their original length to have potential of expressing meibum.³²³ More information is also needed on the benefits of wet versus dry heat^{350, 351} and whether this is based on an individual's ocular surface biomarkers. In the TFOS DEWS II management report, we identified there are few dry eye treatment direct comparator trials, rather new treatments are evaluated against a placebo.³²⁹ Hence, before this is available, we conducted a survey of eyecare practitioner practice across the globe identifying how they currently use treatments based on dry eye disease severity and subtype;³⁵² this should allow practitioners to benchmark their practice as well as identifying those comparisons that need research evidence.

Using our now widely accepted TFOS Dry Eye Workshop II criteria²⁹⁰ of symptoms (OSDI score of ≥ 13 or DEQ-5 score of ≥ 6) and at least one homeostasis marker (non-invasive breakup time < 10 s; tear film hyperosmolarity defined either by the highest osmolarity value of ≥ 308 mOsm/l among eyes or

an interocular osmolarity difference of $>8\text{mOsm/l}$; or ocular surface damage defined either by >5 corneal staining spots, >9 conjunctival staining spots, or a LWE staining of $\geq 2\text{mm}$ length and $\geq 25\%$ width), we found the prevalence of dry eye to be 32% in a demographically representative population in the United Kingdom³⁰⁷, 58% in a Mediterranean population³⁰⁶ and it have been reported as 18% across Asia.³⁵³

Ocular allergy is also common and affects the ocular surface.³⁵⁴ There is much overlap with dry eye disease³⁵⁵ and while we have confirmed it is conventional to apply pharmaceutical treatments,^{356, 357} we demonstrated that non-pharmaceutical artificial tear and cold compress approaches can be equally effective in acute disease symptomology.³⁵⁸ While contact lenses were considered a contraindication, the use of daily disposables have been found to protect the ocular surface and reduce symptomology^{213, 214} and there is now a drug delivering contact lens system for a combined antihistamine and mast cell stabiliser.³⁵⁹




Figure 4: TFOS compliance diagnosis and management algorithm built on current research evidence. NIBUT = non-invasive tear breakup time; TMH = tear meniscus height; MG = meibomian gland; IPL = intense pulsed light therapy; LLLT = low level light therapy.

Conclusions

While technology is driving many of the lifestyle changes that are driving the myopia epidemic and increase in dry eye disease, for example, it also can be utilised to allow more sensitive and detailed evaluation of the eye and its management. Assessment of visual function and eye focus has been improved through modern techniques and instrumentation. Mobile technology can aid practitioners in capturing data and communicating with patients. It can also be used by patients to monitor their condition, to aid compliance with prescribed medication and to even enhance their visual input. Advancements in optical medical devices including spectacle, contact and intraocular lenses, have allowed for a better understanding of the mechanism, and management of presbyopia and myopia control. Enhancements in imaging technology have enabled improved quantitative and qualitative assessment of the tear film and ocular surface, informing diagnosis and treatment strategies. Optometrists play a key role in translating research to inform their clinical practice, adopting relevant technology to enhance their clinical assessment of their patients to allow sensitive and detailed evaluation of the eye and its management.

Funding /Support

This body of work has been supported by the Engineering and Physical Science Research Council, Innovate UK, National Institute for Health Research, the European Union (European Regional Development Fund, Mari-Curie), charities and multiple industry partners.

Conflict of Interest Disclosures

I am a co-founder of Eyoto, Aston Vision Sciences and Wolffsohn Research companies.

Author Contributions and Acknowledgements

Conceptualization: JSW; Funding Acquisition: JSW; Investigation: JSW; Writing – Original Draft: JSW; Writing – Review & Editing: JSW.

I would like to thank the American Academy of Optometry and the American Optometric Foundation for presenting me with the prestigious Glenn A. Fry Award. I would also like to thank my mentors (Neil Charman, Janet Silver, Neville McBrien, Bernard Gilmartin, Brian Tighe and David Sullivan), the many researchers that I have collaborated with in the work discussed in this review including those from Aston University, namely Jeremy Chiang, Leon Davies, Debarun Dutta, Sònia Travé Huarte, Nicola Logan, Shehzad Naroo, Sunil Shah and Amy Sheppard, national / international collaborators, in particular Jennifer Craig (University of Auckland), Lyndon Jones (University of Waterloo), along with Stefan Bandlitz (Höhere Fachschule für Augenoptik und Optometrie Köln), Pauline Cho (Hong

Kong Polytechnic University), Philip Morgan (the University of Manchester), Heiko Pult (University of Cardiff), the British and Irish Committee of university and Colleges Committee of Contact Lens Educators, postdoctoral colleagues and my postgraduates, in particular Paramdeep Bilkhu, Phillip Buckhurst, Tom Drew, Navneet Gupta, Olivia Hunt, Alec Kingsnorth, Rachael Peterson, Christine Purslow, Jacinto Santodomingo-Rubido, and Zimar Sivardeen. In addition, I would like to dedicate this paper to my parents for all the opportunities they gave me, my supportive family, and my wife Rachel and son Peter, to whom I owe my career.

References

1. Wolffsohn JS. Keratometry - a Technique That Should Be Relegated to the Clinical Dark Ages? *Cont Lens Anterior Eye* 2017;40:357-9.
2. Wolffsohn JS, Peterson RC. Anterior Ophthalmic Imaging. *Clin Exp Optom* 2006;89:205-14.
3. Sloan LL. Measurement of Visual Acuity; a Critical Review. *AMA Arch Ophthalmol* 1951;45:704-25.
4. Reinecke RD, Cogan DG. Standardization of Objective Visual Acuity Measurements; Optokinetic Nystagmus Vs. Snellen Acuity. *AMA Arch Ophthalmol* 1958;60:418-21.
5. Bailey IL, Lovie JE. New Design Principles for Visual Acuity Letter Charts. *Am J Optom Physiol Opt* 1976;53:740-5.
6. Wolffsohn JS, Cochrane AL. The Practical near Acuity Chart (Pnac) and Prediction of Visual Ability at Near. *Ophthalmic Physiol Opt* 2000;20:90-7.
7. Bailey IL, Lovie JE. The Design and Use of a New near-Vision Chart. *Am J Optom Physiol Opt* 1980;57:378-87.
8. Sloan LL. New Test Charts for the Measurement of Visual Acuity at Far and near Distances. *Am J Ophthalmol* 1959;48:807-13.
9. Pieh S, Kellner C, Hanselmayer G, et al. Comparison of Visual Acuities at Different Distances and Defocus Curves. *J Cataract Refract Surg* 2002;28:1964-7.
10. Maxwell WA, Cionni RJ, Lehmann RP, Modi SS. Functional Outcomes after Bilateral Implantation of Apodized Diffractive Aspheric Acrylic Intraocular Lenses with a +3.0 or +4.0 Diopter Addition Power Randomized Multicenter Clinical Study. *J Cataract Refract Surg* 2009;35:2054-61.
11. Hayashi K, Manabe S, Hayashi H. Visual Acuity from Far to near and Contrast Sensitivity in Eyes with a Diffractive Multifocal Intraocular Lens with a Low Addition Power. *J Cataract Refract Surg* 2009;35:2070-6.
12. Schmidinger G, Geitzenauer W, Hahsle B, et al. Depth of Focus in Eyes with Diffractive Bifocal and Refractive Multifocal Intraocular Lenses. *J Cataract Refract Surg* 2006;32:1650-6.
13. Knorz MC, Bedoya JH, Hsia TC, et al. Comparison of Modulation Transfer Function and through Focus Response with Monofocal and Bifocal IOLs. *German J Ophthalmol* 1992;1:45-53.
14. Ciuffreda KJ, Hokoda SC, Hung GK, et al. Static Aspects of Accommodation in Human Amblyopia. *Am J Optom Physiol Opt* 1983;60:436-49.
15. Gupta N, Naroo SA, Wolffsohn JS. Is Randomisation Necessary for Measuring Defocus Curves in Pre-Presbyopes? *Cont Lens Anterior Eye* 2007;30:119-24.
16. Gupta N, Wolffsohn JS, Naroo SA. Optimizing Measurement of Subjective Amplitude of Accommodation with Defocus Curves. *J Cataract Refract Surg* 2008;34:1329-38.
17. Wolffsohn JS, Jinabhai AN, Kingsnorth A, et al. Exploring the Optimum Step Size for Defocus Curves. *J Cataract Refract Surg* 2013;39:873-80.
18. Buckhurst PJ, Wolffsohn JS, Naroo SA, et al. Multifocal Intraocular Lens Differentiation Using Defocus Curves. *Invest Ophthalmol Vis Sci* 2012;53:3920-6.
19. Leibowitz HW, Owens DA. Anomalous Myopias and the Intermediate Dark Focus of Accommodation. *Science* 1975;189:646-8.

20. Owens DA. The Resting State of the Eyes: Our Ability to See under Adverse Conditions Depends on the Involuntary Focus and Convergence of Our Eyes at Rest. *Am Scientist* 1984;72:378-87.
21. McBrien NA, Millodot M. Clinical Evaluation of the Canon Autorefractometer R-1. *Am J Optom Physiol Opt* 1985;62:786-92.
22. Davies LN, Mallen EA, Wolffsohn JS, Gilmartin B. Clinical Evaluation of the Shin-Nippon Nvision-K 5001/Grand Seiko Wr-5100k Autorefractor. *Optom Vis Sci* 2003;80:320-4.
23. Hunt OA, Wolffsohn JS, Gilmartin B. Evaluation of the Measurement of Refractive Error by the Powerrefractor: A Remote, Continuous and Binocular Measurement System of Oculomotor Function. *Br J Ophthalmol* 2003;87:1504-8.
24. Mallen EA, Gilmartin B, Wolffsohn JS, Tsujimura S. Clinical Evaluation of the Shin-Nippon Srw-5000 Autorefractor in Adults: An Update. *Ophthalmic Physiol Opt* 2015;35:622-7.
25. Mallen EA, Wolffsohn JS, Gilmartin B, Tsujimura S. Clinical Evaluation of the Shin-Nippon Srw-5000 Autorefractor in Adults. *Ophthalmic Physiol Opt* 2001;21:101-7.
26. Wolffsohn JS, Davies LN, Naroo SA, et al. Evaluation of an Open-Field Autorefractor's Ability to Measure Refraction and Hence Potential to Assess Objective Accommodation in Pseudophakes. *Br J Ophthalmol* 2011;95:498-501.
27. Bhatt UK, Sheppard AL, Shah S, et al. Design and Validity of a Miniaturized Open-Field Aberrometer. *J Cataract Refract Surg* 2013;39:36-40.
28. Horwood AM. When Does Blur Matter? A Narrative Review and Commentary. *J Binoc Vis Ocular Motility* 2022;72:57-68.
29. Dhallu SK, Sheppard AL, Drew T, et al. Factors Influencing Pseudo-Accommodation-the Difference between Subjectively Reported Range of Clear Focus and Objectively Measured Accommodation Range. *Vision* 2019;3.
30. Vilupuru AS, Kasthurirangan S, Glasser A. Dynamics of Accommodative Fatigue in Rhesus Monkeys and Humans. *Vision Res* 2005;45:181-91.
31. Wolffsohn JS, Sheppard AL, Vakani S, Davies LN. Accommodative Amplitude Required for Sustained near Work. *Ophthalmic Physiol Opt* 2011;31:480-6.
32. Wick B, London R. Analysis of Binocular Visual Function Using Tests Made under Binocular Conditions. *Am J Optom Physiol Opt* 1987;64:227-40.
33. Mallen EA, Gilmartin B, Wolffsohn JS. Sympathetic Innervation of Ciliary Muscle and Oculomotor Function in Emmetropic and Myopic Young Adults. *Vision Res* 2005;45:1641-51.
34. Wolffsohn JS, Gilmartin B, Mallen EA, Tsujimura S. Continuous Recording of Accommodation and Pupil Size Using the Shin-Nippon Srw-5000 Autorefractor. *Ophthalmic Physiol Opt* 2001;21:108-13.
35. Wolffsohn JS, Hunt OA, Gilmartin B. Continuous Measurement of Accommodation in Human Factor Applications. *Ophthalmic Physiol Opt* 2002;22:380-4.
36. Wolffsohn JS, O'Donnell C, Charman WN, Gilmartin B. Simultaneous Continuous Recording of Accommodation and Pupil Size Using the Modified Shin-Nippon Srw-5000 Autorefractor. *Ophthalmic Physiol Opt* 2004;24:142-7.
37. Wolffsohn JS, Ukai K, Gilmartin B. Dynamic Measurement of Accommodation and Pupil Size Using the Portable Grand Seiko Fr-5000 Autorefractor. *Optom Vis Sci* 2006;83:306-10.
38. Pugh JR, Winn B. A Procedural Guide to the Modification of a Canon Autorefractometer R-1 for Use as a Continuously Recording Optometer. *Ophthalmic Physiol Opt* 1989;9:451-4.
39. Winn B, Pugh JR, Gilmartin B, Owens H. The Effect of Pupil Size on Static and Dynamic Measurements of Accommodation Using an Infra-Red Optometer. *Ophthalmic Physiol Opt* 1989;9:277-83.
40. Wolffsohn JS, Hunt OA, Naroo S, et al. Objective Accommodative Amplitude and Dynamics with the 1cu Accommodative Intraocular Lens. *Invest Ophthalmol Vis Sci* 2006;47:1230-5.
41. Sheppard AL, Bashir A, Wolffsohn JS, Davies LN. Accommodating Intraocular Lenses: A Review of Design Concepts, Usage and Assessment Methods. *Clin Exp Optom* 2010;93:441-52.

42. Wolffsohn JS, Naroo SA, Motwani NK, et al. Subjective and Objective Performance of the Lenstec Kh-3500 "Accommodative" Intraocular Lens. *Br J Ophthalmol* 2006;90:693-6.
43. Wolffsohn JS, Davies LN, Gupta N, et al. Mechanism of Action of the Tetraflex Accommodative Intraocular Lens. *J Refract Surg* 2010;26:858-62.
44. Manns F, Parel JM, Denham D, et al. Optomechanical Response of Human and Monkey Lenses in a Lens Stretcher. *Invest Ophthalmol Vis Sci* 2007;48:3260-8.
45. Webb JN, Dong C, Bernal A, Scarcelli G. Simulating the Mechanics of Lens Accommodation Via a Manual Lens Stretcher. *Journal of visualized experiments : JoVE* 2018;132:57162.
46. Ziebarth NM, Borja D, Arrieta E, et al. Role of the Lens Capsule on the Mechanical Accommodative Response in a Lens Stretcher. *Invest Ophthalmol Vis Sci* 2008;49:4490-6.
47. Wei H, Wolffsohn JS, Gomes de Oliveira O, Davies LN. Characterisation and Modelling of an Artificial Lens Capsule Mimicking Accommodation of Human Eyes. *Polymers* 2021;13:3916.
48. Wei H, Wolffsohn JS, Gomes de Oliveira O, Davies LN. An Artificial Lens Capsule with a Lens Radial Stretching System Mimicking Dynamic Eye Focusing. *Polymers* 2021;13:3552.
49. Rosin B, Banin E, Sahel JA. Current Status of Clinical Trials Design and Outcomes in Retinal Gene Therapy. *Cold Spring Harbor perspectives in medicine* 2023;Sep 11:a041301.
50. Gupta N, Wolffsohn JS, Naroo SA. Comparison of near Visual Acuity and Reading Metrics in Presbyopia Correction. *J Cataract Refract Surg* 2009;35:1401-9.
51. Yeatman JD, White AL. Reading: The Confluence of Vision and Language. *Annual review of vision science* 2021;7:487-517.
52. Sacconaghi M. Why the American Public Supports Twenty-First Century Learning. *New directions for youth development* 2006;39-45, 11-2.
53. Radner W. Reading Charts in Ophthalmology. *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie* 2017;255:1465-82.
54. Latham K, Tabrett DR. Guidelines for Predicting Performance with Low Vision Aids. *Optom Vis Sci* 2012;89:1316-26.
55. Whittaker SG, Lovie-Kitchin J. Visual Requirements for Reading. *Optom Vis Sci* 1993;70:54-65.
56. Cheong AC, Lovie-Kitchin JE, Bowers AR. Determining Magnification for Reading with Low Vision. *Clin Exp Optom* 2002;85:229-37.
57. Radner W, Willinger U, Obermayer W, et al. [a New Reading Chart for Simultaneous Determination of Reading Vision and Reading Speed]. *Klinische Monatsblätter fur Augenheilkunde* 1998;213:174-81.
58. Stifter E, König F, Lang T, et al. Reliability of a Standardized Reading Chart System: Variance Component Analysis, Test-Retest and Inter-Chart Reliability. *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie* 2004;242:31-9.
59. Legge GE, Ross JA, Luebker A, LaMay JM. Psychophysics of Reading. Viii. The Minnesota Low-Vision Reading Test. *Optom Vis Sci* 1989;66:843-53.
60. Patel B, Elliott DB, Whitaker D. Optimal Reading Speed in Simulated Cataract: Development of a Potential Vision Test. *Ophthalmic Physiol Opt* 2001;21:272-6.
61. Calabrèse A, To L, He Y, et al. Comparing Performance on the Mnread Ipad Application with the Mnread Acuity Chart. *J Vis* 2018;18:8.
62. Kingsnorth A, Wolffsohn JS. Mobile App Reading Speed Test. *Br J Ophthalmol* 2015;99:536-9.
63. Pelli DG, Robson JG, Wilkins AJ. The Design of a New Letter Chart for Measuring Contrast Sensitivity. *Clin Vis Sc* 1988;2:187-99.
64. Pomerance GN, Evans DW. Test-Retest Reliability of the Csv-1000 Contrast Test and Its Relationship to Glaucoma Therapy. *Invest Ophthalmol Vis Sci* 1994;35:3357-61.
65. Corwin TR, Richman JE. Three Clinical Tests of the Spatial Contrast Sensitivity Function: A Comparison. *American journal of optometry and physiological optics* 1986;63:413-8.

66. Campbell FW, Robson JG. Application of Fourier Analysis to Modulation Response of Eye. *J Opt Soc Am* 1964;54:581.
67. Kingsnorth A, Drew T, Grewal B, Wolffsohn JS. Mobile App Aston Contrast Sensitivity Test. *Clin Exp Optom* 2016;99:350-5.
68. Tardif J, Watson MR, Giaschi D, Gosselin F. The Curve Visible on the Campbell-Robson Chart Is Not the Contrast Sensitivity Function. *Frontiers in neuroscience* 2021;15:626466.
69. Karam M, Alkhowaiter N, Alkhabbaz A, et al. Extended Depth of Focus Versus Trifocal for Intraocular Lens Implantation: An Updated Systematic Review and Meta-Analysis. *American Journal of Ophthalmology* 2023;251:52-70.
70. Boadi-Kusi SB, Austin E, Abu SL, et al. Disability Glare and Nighttime Driving Performance among Commercial Drivers in Ghana. *Journal of occupational health* 2021;63:e12279.
71. Hamedani M, Dulley B, Murdoch I. Glaucoma and Glare. *Eye* 2021;35:1741-7.
72. McAlinden C, Pesudovs K, Moore JE. The Development of an Instrument to Measure Quality of Vision: The Quality of Vision (Qov) Questionnaire. *Invest Ophthalmol Vis Sci* 2010;51:5537-45.
73. Holladay JT, Prager TC, Trujillo J, Ruiz RS. Brightness Acuity Test and Outdoor Visual Acuity in Cataract Patients. *J Cataract Refract Surg* 1987;13:67-9.
74. Williamson TH, Strong NP, Sparrow J, et al. Contrast Sensitivity and Glare in Cataract Using the Pelli-Robson Chart. *Br J Ophthalmol* 1992;76:719-22.
75. Niesen U, Businger U, Hartmann P, et al. Glare Sensitivity and Visual Acuity after Excimer Laser Photorefractive Keratectomy for Myopia. *Br J Ophthalmol* 1997;81:136-40.
76. Elliot RH. A Halometer. *Br Med J* 1924;1:624.
77. Hunkeler JD, Coffman TM, Paugh J, et al. Characterization of Visual Phenomena with the Array Multifocal Intraocular Lens. *J Cataract Refract Surg* 2002;28:1195-204.
78. Wachler Brian SB, Hiatt D, Chou B, Christie Jonathan P. Reduction of Pupil Size and Halos with Minus Lenses after Laser in Situ Keratomileusis. *J Refract Surg* 2004;20:149-54.
79. Buckhurst PJ, Naroo SA, Davies LN, et al. Tablet App Halometer for the Assessment of Dysphotopsia. *J Cataract Refract Surg* 2015;41:2424-9.
80. Buckhurst PJ, Naroo SA, Davies LN, et al. Assessment of Dysphotopsia in Pseudophakic Subjects with Multifocal Intraocular Lenses. *BMJ Open Ophthalmol* 2017;1:e000064.
81. Sheppard AL, Shah S, Bhatt U, et al. Visual Outcomes and Subjective Experience after Bilateral Implantation of a New Diffractive Trifocal Intraocular Lens. *J Cataract Refract Surg* 2013;39:343-9.
82. Food and Drug Administration F. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims In; <https://www.fda.gov/media/77832/download> 2009.
83. Mitchell J, Wolffsohn J, Woodcock A, et al. The Macdqol Individualized Measure of the Impact of Macular Degeneration on Quality of Life: Reliability and Responsiveness. *Am J Ophthalmol* 2008;146:447-54.
84. Mitchell J, Wolffsohn JS, Woodcock A, et al. Psychometric Evaluation of the Macdqol Individualised Measure of the Impact of Macular Degeneration on Quality of Life. *Health Qual Life Outcomes* 2005;3:25.
85. Perez-Mana L, Cardona G, Pardo Cladellas Y, et al. Translation and Cultural Adaptation into Spanish of the Low Vision Quality of Life Questionnaire. *Arch Soc Esp Oftalmol (Engl Ed)* 2019;94:384-90.
86. Perez-Mana L, Cardona G, Pardo-Cladellas Y, et al. Validation of the Spanish Version of the Low Vision Quality of Life Questionnaire. *J Optom* 2022;15:199-209.
87. Wolffsohn JS, Cochrane AL. Design of the Low Vision Quality-of-Life Questionnaire (Lvqol) and Measuring the Outcome of Low-Vision Rehabilitation. *Am J Ophthalmol* 2000;130:793-802.
88. Zou H, Zhang X, Xu X, et al. Development and Psychometric Tests of the Chinese-Version Low Vision Quality of Life Questionnaire. *Qual Life Res* 2005;14:1633-9.

89. Wolffsohn JS, Jackson J, Hunt OA, et al. An Enhanced Functional Ability Questionnaire (Faviq) to Measure the Impact of Rehabilitation Services on the Visually Impaired. *Int J Ophthalmol* 2014;7:77-85.
90. Ehrlich JR, Spaeth GL, Carlozzi NE, Lee PP. Patient-Centered Outcome Measures to Assess Functioning in Randomized Controlled Trials of Low-Vision Rehabilitation: A Review. *The patient* 2017;10:39-49.
91. Buckhurst PJ, Wolffsohn JS, Gupta N, et al. Development of a Questionnaire to Assess the Relative Subjective Benefits of Presbyopia Correction. *J Cataract Refract Surg* 2012;38:74-9.
92. Zeri F, Beltramo I, Boccardo L, et al. An Italian Translation and Validation of the near Activity Visual Questionnaire (Navq). *Eur J Ophthalmol* 2017;27:640-5.
93. Gupta N, Wolffsohn JS, Naroo SA, et al. Development of a near Activity Visual Questionnaire to Assess Accommodating Intraocular Lenses. *Cont Lens Anterior Eye* 2007;30:134-43.
94. Findley A, Sharma G, Bentley S, et al. Comparison of Literature Review, Social Media Listening, and Qualitative Interview Research Methods in Generating Patient-Reported Symptom and Functional Impact Concepts of Presbyopia. *Ophthalmol Ther* 2023;12:501-16.
95. Wolffsohn JS, Leteneux-Pantais C, Chiva-Razavi S, et al. Social Media Listening to Understand the Lived Experience of Presbyopia: Systematic Search and Content Analysis Study. *J Med Internet Res* 2020;22:e18306.
96. Bentley S, Findley A, Chiva-Razavi S, et al. Evaluation of the Content Validity of Patient-Reported Outcome (Pro) Instruments Developed for Use with Individuals with Phakic Presbyopia, Including the near Activity Visual Questionnaire-Presbyopia (Navq-P) and the near Vision Correction Independence (Nvci) Instrument. *J Patient Rep Outcomes* 2021;5:109.
97. Sharma G, Chiva-Razavi S, Viriato D, et al. Patient-Reported Outcome Measures in Presbyopia: A Literature Review. *BMJ Open Ophthalmol* 2020;5:e000453.
98. Wolffsohn JS, Cochrane AL, Watt NA. Implementation Methods for Vision Related Quality of Life Questionnaires. *Br J Ophthalmol* 2000;84:1035-40.
99. Bull C, Byrnes J, Hettiarachchi R, Downes M. A Systematic Review of the Validity and Reliability of Patient-Reported Experience Measures. *Health services research* 2019;54:1023-35.
100. Churruca K, Pomare C, Ellis LA, et al. Patient-Reported Outcome Measures (Proms): A Review of Generic and Condition-Specific Measures and a Discussion of Trends and Issues. *Health expectations : an international journal of public participation in health care and health policy* 2021;24:1015-24.
101. Pesudovs K. Item Banking: A Generational Change in Patient-Reported Outcome Measurement. *Optom Vis Sci* 2010;87:285-93.
102. Chong MF, Jackson AJ, Wolffsohn JS, Bentley SA. An Update on the Characteristics of Patients Attending the Kooyong Low Vision Clinic. *Clin Exp Optom* 2016;99:555-8.
103. Wolffsohn JS, Cochrane AL. Low Vision Perspectives on Glaucoma. *Clin Exp Optom* 1998;81:280-9.
104. Wolffsohn JS, Cochrane AL. The Changing Face of the Visually Impaired: The Kooyong Low Vision Clinic's Past, Present, and Future. *Optom Vis Sci* 1999;76:747-54.
105. Virgili G, Acosta R, Bentley SA, et al. Reading Aids for Adults with Low Vision. *The Cochrane database of systematic reviews* 2018;4:Cd003303.
106. Bailie M, Wolffsohn JS, Stevenson M, Jackson AJ. Functional and Perceived Benefits of Wearing Coloured Filters by Patients with Age-Related Macular Degeneration. *Clin Exp Optom* 2013;96:450-4.
107. Wolffsohn JS, Dinardo C, Vingrys AJ. Benefit of Coloured Lenses for Age-Related Macular Degeneration. *Ophthalmic Physiol Opt* 2002;22:300-11.
108. Eperjesi F, Fowler CW, Evans BJ. Do Tinted Lenses or Filters Improve Visual Performance in Low Vision? A Review of the Literature. *Ophthalmic Physiol Opt* 2002;22:68-77.
109. Bailey IL, Bullimore MA, Greer RB, Mattingly WB. Low Vision Magnifiers-Their Optical Parameters and Methods for Prescribing. *Optom Vis Sci* 1994;71:689-98.

110. Carkeet A. Stand Magnifiers for Low Vision: Description, Prescription, Assessment. *Clin Exp Optom* 2020;103:11-20.
111. Wolffsohn JS, Palmer E, Rubinstein M, Eperjesi F. Effect of Light-Emitting Diode Colour Temperature on Magnifier Reading Performance of the Visually Impaired. *Clin Exp Optom* 2012;95:510-4.
112. Peterson RC, Wolffsohn JS, Rubinstein M, Lowe J. Benefits of Electronic Vision Enhancement Systems (Eves) for the Visually Impaired. *Am J Ophthalmol* 2003;136:1129-35.
113. Wolffsohn JS, Peterson RC. A Review of Current Knowledge on Electronic Vision Enhancement Systems for the Visually Impaired. *Ophthalmic Physiol Opt* 2003;23:35-42.
114. Ehrlich JR, Ojeda LV, Wicker D, et al. Head-Mounted Display Technology for Low-Vision Rehabilitation and Vision Enhancement. *Am J Ophthalmol* 2017;176:26-32.
115. Taylor JJ, Bambrick R, Brand A, et al. Effectiveness of Portable Electronic and Optical Magnifiers for near Vision Activities in Low Vision: A Randomised Crossover Trial. *Ophthalmic Physiol Opt* 2017;37:370-84.
116. Wolffsohn JS, Mukhopadhyay D, Rubinstein M. Image Enhancement of Real-Time Television to Benefit the Visually Impaired. *Am J Ophthalmol* 2007;144:436-40.
117. Crossland MD, Starke SD, Imielski P, et al. Benefit of an Electronic Head-Mounted Low Vision Aid. *Ophthalmic Physiol Opt* 2019;39:422-31.
118. Golubova E, Starke SD, Crossland MD, Wolffsohn JS. Design Considerations for the Ideal Low Vision Aid: Insights from De-Brief Interviews Following a Real-World Recording Study. *Ophthalmic Physiol Opt* 2021;41:266-80.
119. Starke SD, Golubova E, Crossland MD, Wolffsohn JS. Everyday Visual Demands of People with Low Vision: A Mixed Methods Real-Life Recording Study. *J Vis* 2020;20:3.
120. Lovie-Kitchin JE, Woo GC. Effect of Magnification and Field of View on Reading Speed Using a Cctv. *Ophthalmic Physiol Opt* 1988;8:139-45.
121. Wolffsohn JS, Eperjesi F. Predicting Prescribed Magnification. *Ophthalmic Physiol Opt* 2004;24:334-8.
122. Huntjens B, Basi M, Nagra M. Evaluating a New Objective Grading Software for Conjunctival Hyperaemia. *Cont Lens Anterior Eye* 2020;43:137-43.
123. Schulze MM, Hutchings N, Simpson TL. The Perceived Bulbar Redness of Clinical Grading Scales. *Optom Vis Sci* 2009;86:E1250-8.
124. Wolffsohn JS, Naroo SA, Christie C, et al. Anterior Eye Health Recording. *Cont Lens Anterior Eye* 2015;38:266-71.
125. Fieguth P, Simpson T. Automated Measurement of Bulbar Redness. *Invest Ophthalmol Vis Sci* 2002;43:340-7.
126. Wolffsohn JS, Purslow C. Clinical Monitoring of Ocular Physiology Using Digital Image Analysis. *Cont Lens Anterior Eye* 2003;26:27-35.
127. Wolffsohn JS. Incremental Nature of Anterior Eye Grading Scales Determined by Objective Image Analysis. *Br J Ophthalmol* 2004;88:1434-8.
128. Chong E, Simpson T, Fonn D. The Repeatability of Discrete and Continuous Anterior Segment Grading Scales. *Optom Vis Sci* 2000;77:244-51.
129. Bailey IL, Bullimore MA, Raasch TW, Taylor HR. Clinical Grading and the Effects of Scaling. *Invest Ophthalmol Vis Sci* 1991;32:422-32.
130. Vianya-Estopa M, Nagra M, Cochrane A, et al. Optimising Subjective Anterior Eye Grading Precision. *Cont Lens Anterior Eye* 2020;43:489-92.
131. Peterson RC, Wolffsohn JS. Objective Grading of the Anterior Eye. *Optom Vis Sci* 2009;86:273-8.
132. O'Donnell C, Wolffsohn JS. Grading of Corneal Transparency. *Cont Lens Anterior Eye* 2004;27:161-70.
133. Peterson RC, Wolffsohn JS. The Effect of Digital Image Resolution and Compression on Anterior Eye Imaging. *Br J Ophthalmol* 2005;89:828-30.

134. Peterson RC, Wolffsohn JS. Sensitivity and Reliability of Objective Image Analysis Compared to Subjective Grading of Bulbar Hyperaemia. *Br J Ophthalmol* 2007;91:1464-6.
135. Pellegrini M, Bernabei F, Moscardelli F, et al. Assessment of Corneal Fluorescein Staining in Different Dry Eye Subtypes Using Digital Image Analysis. *Translational vision science & technology* 2019;8:34.
136. Pritchard N, Young G, Coleman S, Hunt C. Subjective and Objective Measures of Corneal Staining Related to Multipurpose Care Systems. *Cont Lens Anterior Eye* 2003;26:3-9.
137. Chun YS, Yoon WB, Kim KG, Park IK. Objective Assessment of Corneal Staining Using Digital Image Analysis. *Invest Ophthalmol Vis Sci* 2014;55:7896-903.
138. Vunnava KP, Shetty R, Prabhu SM, et al. Automatic Segmentation and Quantified Analysis of Meibomian Glands from Infrared Images. *Indian journal of ophthalmology* 2023;71:1426-31.
139. Saha RK, Chowdhury AMM, Na KS, et al. Automated Quantification of Meibomian Gland Dropout in Infrared Meibography Using Deep Learning. *Ocul Surf* 2022;26:283-94.
140. Hagan S, Martin E, Enríquez-de-Salamanca A. Tear Fluid Biomarkers in Ocular and Systemic Disease: Potential Use for Predictive, Preventive and Personalised Medicine. *The EPMA journal* 2016;7:15.
141. You J, Willcox MD, Madigan MC, et al. Tear Fluid Protein Biomarkers. *Advances in clinical chemistry* 2013;62:151-96.
142. Khanna RK, Catanese S, Emond P, et al. Metabolomics and Lipidomics Approaches in Human Tears: A Systematic Review. *Surv Ophthalmol* 2022;67:1229-43.
143. Moreddu R, Elsherif M, Adams H, et al. Integration of Paper Microfluidic Sensors into Contact Lenses for Tear Fluid Analysis. *Lab Chip* 2020;20:3970-9.
144. Yetisen AK, Jiang N, Tamayol A, et al. Paper-Based Microfluidic System for Tear Electrolyte Analysis. *Lab Chip* 2017;17:1137-48.
145. Tomlinson A, McCann LC, Pearce EI. Comparison of Human Tear Film Osmolarity Measured by Electrical Impedance and Freezing Point Depression Techniques. *Cornea* 2010;29:1036-41.
146. Kang MJ, Kim HS, Kim MS, Kim EC. The Correlation between Matrix Metalloproteinase-9 Point-of-Care Immunoassay, Tear Film Osmolarity, and Ocular Surface Parameters. *J Ophthalmol* 2022;2022:6132016.
147. Posa A, Bräuer L, Schicht M, et al. Schirmer Strip Vs. Capillary Tube Method: Non-Invasive Methods of Obtaining Proteins from Tear Fluid. *Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft* 2013;195:137-42.
148. Sebbag L, Showman L, McDowell EM, et al. Impact of Flow Rate, Collection Devices, and Extraction Methods on Tear Concentrations Following Oral Administration of Doxycycline in Dogs and Cats. *Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics* 2018;34:452-9.
149. Garcia-Porta N, Mann A, Saez-Martinez V, et al. The Potential Influence of Schirmer Strip Variables on Dry Eye Disease Characterisation, and on Tear Collection and Analysis. *Cont Lens Anterior Eye* 2018;41:47-53.
150. Bjerrum KB, Prause JU. Collection and Concentration of Tear Proteins Studied by Sds Gel Electrophoresis. Presentation of a New Method with Special Reference to Dry Eye Patients. *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie* 1994;232:402-5.
151. Peterson RC, Gorbet M, Cirra D, et al. Non-Invasive Collection and Examination of Human Corneal Epithelial Cells. *Optom Vis Sci* 2011;88:1317-25.
152. Wolffsohn JS, Davies LN. Advances in Anterior Segment Imaging. *Curr Opin Ophthalmol* 2007;18:32-8.
153. Kaur K, Gurnani B. Slit-Lamp Biomicroscope. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing 2023.

154. Ahmed F, House RJ, Feldman BH. Corneal Abrasions and Corneal Foreign Bodies. Primary care 2015;42:363-75.
155. Dang DH, Riaz KM, Karamichos D. Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets. Drugs 2022;82:145-67.
156. Peterson RC, Wolffsohn JS, Fowler CW. Optimization of Anterior Eye Fluorescein Viewing. Am J Ophthalmol 2006;142:572-5.
157. Rowsey JJ, Reynolds AE, Brown R. Corneal Topography. Corneoscope. Archives of ophthalmology (Chicago, Ill : 1960) 1981;99:1093-100.
158. Alonso-Caneiro D, Iskander DR, Collins MJ. Tear Film Surface Quality with Soft Contact Lenses Using Dynamic-Area High-Speed Videokeratoscopy. Eye Contact Lens 2009;35:227-31.
159. Forst G. Observation of Two Structures of the Tear Film Lipid Layer. Ophthalmic Physiol Opt 1988;8:190-2.
160. Swiderska K, Read ML, Blackie CA, et al. Latest Developments in Meibography: A Review. Ocul Surf 2022;25:119-28.
161. Best N, Drury L, Wolffsohn JS. Clinical Evaluation of the Oculus Keratograph. Cont Lens Anterior Eye 2012;35:171-4.
162. Zhang G, Cao H, Qu C. Efficacy, Safety, Predictability, and Stability of Lasik for Presbyopia Correction: A Systematic Review and Meta-Analysis. J Refract Surg 2023;39:627-38.
163. Molina-Martín A, Piñero DP, Martínez-Plaza E, et al. Efficacy of Presbyopia-Correcting Contact Lenses: A Systematic Review. Eye Contact Lens 2023;49:319-28.
164. Wolffsohn JS, Davies LN. Presbyopia: Effectiveness of Correction Strategies. Prog Retin Eye Res 2019;68:124-43.
165. Sieburth R, Chen M. Intraocular Lens Correction of Presbyopia. Taiwan journal of ophthalmology 2019;9:4-17.
166. Pucker AD, Tichenor AA. A Review of Contact Lens Dropout. Clinical optometry 2020;12:85-94.
167. Best N, Drury L, Wolffsohn JS. Predicting Success with Silicone-Hydrogel Contact Lenses in New Wearers. Cont Lens Anterior Eye 2013;36:232-7.
168. Markoulli M, Kolanu S. Contact Lens Wear and Dry Eyes: Challenges and Solutions. Clinical optometry 2017;9:41-8.
169. Schafer J, Mitchell GL, Chalmers RL, et al. The Stability of Dryness Symptoms after Refitting with Silicone Hydrogel Contact Lenses over 3 Years. Eye Contact Lens 2007;33:247-52.
170. Glasson MJ, Stapleton F, Keay L, et al. Differences in Clinical Parameters and Tear Film of Tolerant and Intolerant Contact Lens Wearers. Invest Ophthalmol Vis Sci 2003;44:5116-24.
171. Belda-Salmeron L, Drew T, Hall L, Wolffsohn JS. Objective Analysis of Contact Lens Fit. Cont Lens Anterior Eye 2015;38:163-7.
172. Boychev N, Loughton DS, Bharwani G, et al. How Should Initial Fit Inform Soft Contact Lens Prescribing. Cont Lens Anterior Eye 2016;39:227-33.
173. Hall LA, Young G, Wolffsohn JS, Riley C. The Influence of Corneoscleral Topography on Soft Contact Lens Fit. Invest Ophthalmol Vis Sci 2011;52:6801-6.
174. Wolffsohn JS, Hunt OA, Basra AK. Simplified Recording of Soft Contact Lens Fit. Cont Lens Anterior Eye 2009;32:37-42.
175. Wolffsohn JS, van der Worp E, de Brabander J, Group GPC. Consensus on Recording of Gas Permeable Contact Lens Fit. Cont Lens Anterior Eye 2013;36:299-303.
176. Young G, Hall L, Sulley A, et al. Inter-Relationship of Soft Contact Lens Diameter, Base Curve Radius, and Fit. Optom Vis Sci 2017;94:458-65.
177. Wolffsohn J, Hall L, Mroczkowska S, et al. The Influence of End of Day Silicone Hydrogel Daily Disposable Contact Lens Fit on Ocular Comfort, Physiology and Lens Wettability. Cont Lens Anterior Eye 2015;38:339-44.
178. Santodomingo-Rubido J, Gilmartin B, Wolffsohn J. Refractive and Biometric Changes with Silicone Hydrogel Contact Lenses. Optom Vis Sci 2005;82:481-9.

179. Santodomingo-Rubido J, Wolffsohn JS, Gilmartin B. Changes in Ocular Physiology, Tear Film Characteristics, and Symptomatology with 18 Months Silicone Hydrogel Contact Lens Wear. *Optom Vis Sci* 2006;83:73-81.
180. Santodomingo-Rubido J, Wolffsohn JS, Gilmartin B. Adverse Events and Discontinuations During 18 Months of Silicone Hydrogel Contact Lens Wear. *Eye Contact Lens* 2007;33:288-92.
181. Santodomingo-Rubido J, Wolffsohn J, Gilmartin B. Conjunctival Epithelial Flaps with 18 Months of Silicone Hydrogel Contact Lens Wear. *Eye Contact Lens* 2008;34:35-8.
182. Wolffsohn JS, Mroczkowska S, Hunt OA, et al. Crossover Evaluation of Silicone Hydrogel Daily Disposable Contact Lenses. *Optom Vis Sci* 2015;92:1063-8.
183. Sivardeen A, Laughton D, Wolffsohn JS. Randomized Crossover Trial of Silicone Hydrogel Presbyopic Contact Lenses. *Optom Vis Sci* 2016;93:141-9.
184. Purslow C, Wolffsohn JS, Santodomingo-Rubido J. The Effect of Contact Lens Wear on Dynamic Ocular Surface Temperature. *Cont Lens Anterior Eye* 2005;28:29-36.
185. Purslow C, Wolffsohn J. The Relation between Physical Properties of the Anterior Eye and Ocular Surface Temperature. *Optom Vis Sci* 2007;84:197-201.
186. Cardall M, Naroo SA, Wolffsohn JS. A Novel, Dynamic, in Vivo, Non-Contact Method of Measuring Oxygen Depletion Rate of the Anterior Eye. *Cont Lens Anterior Eye* 2011;34:121-7.
187. Peterson RC, Wolffsohn JS, Nick J, et al. Clinical Performance of Daily Disposable Soft Contact Lenses Using Sustained Release Technology. *Cont Lens Anterior Eye* 2006;29:127-34.
188. Mahomed A, Wolffsohn JS, Tighe BJ. Structural Design of Contact Lens-Based Drug Delivery Systems; in Vitro and in Vivo Studies of Ocular Triggering Mechanisms. *Cont Lens Anterior Eye* 2016;39:97-105.
189. Wolffsohn JS, Hunt OA, Chowdhury A. Objective Clinical Performance of 'Comfort-Enhanced' Daily Disposable Soft Contact Lenses. *Cont Lens Anterior Eye* 2010;33:88-92.
190. Debarun D, Wolffsohn JS. Effect of Large Diameter and Plasma Coating on the Initial Adaptation of Gas Permeable Contact Lens Fitting for Neophytes. *Cont Lens Anterior Eye* 2021;44:76-80.
191. Vidal-Rohr M, Wolffsohn JS, Davies LN, Cervino A. Effect of Contact Lens Surface Properties on Comfort, Tear Stability and Ocular Physiology. *Cont Lens Anterior Eye* 2018;41:117-21.
192. Wolffsohn JS, Tharoo A, Lakhani N. Optimal Time Following Fluorescein Instillation to Evaluate Rigid Gas Permeable Contact Lens Fit. *Cont Lens Anterior Eye* 2015;38:110-4.
193. Bandlitz S, Baumer J, Conrad U, Wolffsohn J. Scleral Topography Analysed by Optical Coherence Tomography. *Cont Lens Anterior Eye* 2017;40:242-7.
194. Bandlitz S, Esper P, Stein M, et al. Corneoscleral Topography Measured with Fourier-Based Profilometry and Scheimpflug Imaging. *Optom Vis Sci* 2020;97:766-74.
195. Bandlitz S, Lagodny M, Kurz C, Wolffsohn JS. Prediction of Anterior Ocular Surface Sagittal Heights Using Placido-Based Corneal Topography in Healthy Eyes. *Ophthalmic Physiol Opt* 2022;42:1023-31.
196. Bergmann B, Wolffsohn JS, Bandlitz S. Scheimpflug Imaging for Grading and Measurement of Corneo-Scleral-Profile in Different Quadrants. *Cont Lens Anterior Eye* 2023;46:101753.
197. Hall LA, Hunt C, Young G, Wolffsohn J. Factors Affecting Corneoscleral Topography. *Invest Ophthalmol Vis Sci* 2013;54:3691-701.
198. Coldrick BJ, Richards C, Sugden K, et al. Developments in Contact Lens Measurement: A Comparative Study of Industry Standard Geometric Inspection and Optical Coherence Tomography. *Cont Lens Anterior Eye* 2016;39:270-6.
199. Wolffsohn JS, Drew T, Dhallu S, et al. Impact of Soft Contact Lens Edge Design and Midperipheral Lens Shape on the Epithelium and Its Indentation with Lens Mobility. *Invest Ophthalmol Vis Sci* 2013;54:6190-7.
200. Jandl A, Ruland T, Schwarz D, et al. Clinical Significance of Contact Lens Related Changes of Ocular Surface Tissue Observed on Optical Coherence Images. *Cont Lens Anterior Eye* 2021;44:101388.

201. Dunne MC, Davies LN, Wolffsohn JS. Accuracy of Cornea and Lens Biometry Using Anterior Segment Optical Coherence Tomography. *J Biomed Opt* 2007;12:064023.
202. Shen M, Cui L, Riley C, et al. Characterization of Soft Contact Lens Edge Fitting Using Ultra-High Resolution and Ultra-Long Scan Depth Optical Coherence Tomography. *Invest Ophthalmol Vis Sci* 2011;52:4091-7.
203. Sorbara L, Simpson TL, Maram J, et al. Optical Edge Effects Create Conjunctival Indentation Thickness Artefacts. *Ophthalmic Physiol Opt* 2015;35:283-92.
204. Chao C, Skidmore K, Tomiyama ES, et al. Soft Toric Contact Lens Wear Improves Digital Performance and Vision-a Randomised Clinical Trial. *Ophthalmic Physiol Opt* 2023;43:25-34.
205. Datta A, Richdale K, Tomiyama ES, et al. Near Visual Function Measured with a Novel Tablet Application in Patients with Astigmatism. *Clin Exp Optom* 2021;104:42-7.
206. Logan AM, Datta A, Skidmore K, et al. Randomized Clinical Trial of near Visual Performance with Digital Devices Using Spherical and Toric Contact Lenses. *Optom Vis Sci* 2020;97:518-25.
207. Wolffsohn JS, Bhogal G, Shah S. Astigmatism and Vision: Should All Astigmatism Always Be Corrected? *Br J Ophthalmol* 2014;98:2-3.
208. Wolffsohn JS, Bhogal G, Shah S. Effect of Uncorrected Astigmatism on Vision. *J Cataract Refract Surg* 2011;37:454-60.
209. Gupta N, Naroo SA, Wolffsohn JS. Visual Comparison of Multifocal Contact Lens to Monovision. *Optom Vis Sci* 2009;86:E98-105.
210. Sivardeen A, Laughton D, Wolffsohn JS. Investigating the Utility of Clinical Assessments to Predict Success with Presbyopic Contact Lens Correction. *Cont Lens Anterior Eye* 2016;39:322-30.
211. Woods J, Woods CA, Fonn D. Early Symptomatic Presbyopes--What Correction Modality Works Best? *Eye Contact Lens* 2009;35:221-6.
212. Sivardeen A, McAlinden C, Wolffsohn JS. Presbyopic Correction Use and Its Impact on Quality of Vision Symptoms. *J Optom* 2020;13:29-34.
213. Wolffsohn JS, Emberlin JC. Role of Contact Lenses in Relieving Ocular Allergy. *Cont Lens Anterior Eye* 2011;34:169-72.
214. Hayes VY, Schnider CM, Veys J. An Evaluation of 1-Day Disposable Contact Lens Wear in a Population of Allergy Sufferers. *Contact Lens and Anterior Eye* 2003;26:85-93.
215. Behar-Cohen F, Baillet G, de Ayguavives T, et al. Ultraviolet Damage to the Eye Revisited: Eye-Sun Protection Factor (E-Spf(R)), a New Ultraviolet Protection Label for Eyewear. *Clin Ophthalmol* 2014;8:87-104.
216. Krutmann J, Behar-Cohen F, Baillet G, et al. Towards Standardization of Uv Eye Protection: What Can Be Learned from Photodermatology? *Photodermatol Photoimmunol Photomed* 2014;30:128-36.
217. Wolffsohn JS, Drew T, Sulley A. Conjunctival Uv Autofluorescence--Prevalence and Risk Factors. *Cont Lens Anterior Eye* 2014;37:427-30.
218. Wolffsohn JS, Dhallu S, Aujla M, et al. International Multi-Centre Study of Potential Benefits of Ultraviolet Radiation Protection Using Contact Lenses. *Cont Lens Anterior Eye* 2022;45:101593.
219. Walker MK, Schornack MM, Vincent SJ. Anatomical and Physiological Considerations in Scleral Lens Wear: Eyelids and Tear Film. *Cont Lens Anterior Eye* 2021;44:101407.
220. Consejo A, Behaegel J, Van Hoey M, et al. Anterior Eye Surface Changes Following Miniscleral Contact Lens Wear. *Cont Lens Anterior Eye* 2019;42:70-4.
221. Dhallu SK, Huarte ST, Bilkhu PS, et al. Effect of Scleral Lens Oxygen Permeability on Corneal Physiology. *Optom Vis Sci* 2020;97:669-75.
222. Lafosse E, Romin DM, Esteve-Taboada JJ, et al. Comparison of the Influence of Corneo-Scleral and Scleral Lenses on Ocular Surface and Tear Film Metrics in a Presbyopic Population. *Cont Lens Anterior Eye* 2018;41:122-7.
223. Wolffsohn JS, Naroo SA, Christie C, et al. History and Symptom Taking in Contact Lens Fitting and Aftercare. *Cont Lens Anterior Eye* 2015;38:258-65.

224. Wolffsohn JS, Dhirajlal H, Vianya-Estopa M, et al. Fast Versus Gradual Adaptation of Soft Daily Disposable Contact Lenses in Neophyte Wearers. *Cont Lens Anterior Eye* 2020;43:268-73.
225. Wolffsohn JS, Ghorbani-Mojarrad N, Vianya-Estopa M, et al. Fast Versus Gradual Adaptation of Soft Monthly Contact Lenses in Neophyte Wearers. *Cont Lens Anterior Eye* 2022;45:101469.
226. Pucker AD, Steele K, Rueff E, et al. Contact Lens Adaption in Neophytes. *Optom Vis Sci* 2021;98:266-71.
227. Wolffsohn JS, Dumbleton K, Huntjens B, et al. Clear - Evidence-Based Contact Lens Practice. *Cont Lens Anterior Eye* 2021;44:368-97.
228. Wolffsohn JS, Morgan PB, Barnett M, et al. Contact Lens Evidence-Based Academic Reports (Clear). *Cont Lens Anterior Eye* 2021;44:129-31.
229. Barnett M, Courey C, Fadel D, et al. Clear - Scleral Lenses. *Cont Lens Anterior Eye* 2021;44:270-88.
230. Jones L, Hui A, Phan CM, et al. Clear - Contact Lens Technologies of the Future. *Cont Lens Anterior Eye* 2021;44:398-430.
231. Richdale K, Cox I, Kollbaum P, et al. Clear - Contact Lens Optics. *Cont Lens Anterior Eye* 2021;44:220-39.
232. Vincent SJ, Cho P, Chan KY, et al. Clear - Orthokeratology. *Cont Lens Anterior Eye* 2021;44:240-69.
233. Morgan PB, Murphy PJ, Gifford KL, et al. Clear - Effect of Contact Lens Materials and Designs on the Anatomy and Physiology of the Eye. *Cont Lens Anterior Eye* 2021;44:192-219.
234. Michaud L, Lipson M, Kramer E, Walker M. The Official Guide to Scleral Lens Terminology. *Cont Lens Anterior Eye* 2020;43:529-34.
235. Sulley A, Dumbleton K. Silicone Hydrogel Daily Disposable Benefits: The Evidence. *Cont Lens Anterior Eye* 2020;43:298-307.
236. Donshik PC. Extended Wear Contact Lenses. *Ophthalmology clinics of North America* 2003;16:305-9.
237. Stapleton F, Bakkar M, Carnt N, et al. Clear - Contact Lens Complications. *Cont Lens Anterior Eye* 2021;44:330-67.
238. Whitmore I. Terminologia Anatomica: New Terminology for the New Anatomist. *The Anatomical record* 1999;257:50-3.
239. Downie LE, Bandlitz S, Bergmanson JPG, et al. Clear - Anatomy and Physiology of the Anterior Eye. *Cont Lens Anterior Eye* 2021;44:132-56.
240. Ashwin PT, Shah S, Wolffsohn JS. Advances in Cataract Surgery. *Clin Exp Optom* 2009;92:333-42.
241. Wolffsohn JS, Davies LN. Intraocular Lenses in the 21st Century. *Clin Exp Optom* 2010;93:377-8.
242. Bhogal-Bhamra GK, Sheppard AL, Kolli S, Wolffsohn JS. Rotational Stability and Centration of a New Toric Lens Design Platform Using Objective Image Analysis over 6 Months. *J Refract Surg* 2019;35:48-53.
243. Buckhurst PJ, Wolffsohn JS, Davies LN, Naroo SA. Surgical Correction of Astigmatism During Cataract Surgery. *Clin Exp Optom* 2010;93:409-18.
244. Buckhurst PJ, Wolffsohn JS, Naroo SA, Davies LN. Rotational and Centration Stability of an Aspheric Intraocular Lens with a Simulated Toric Design. *J Cataract Refract Surg* 2010;36:1523-8.
245. Dhallu SK, Sheppard AL, Wolffsohn JS. Evaluating the Effect of Splitting Cylindrical Power on Improving Patient Tolerance to Toric Lens Misalignment. *Cont Lens Anterior Eye* 2014;37:191-5.
246. Sheppard AL, Wolffsohn JS, Bhatt U, et al. Clinical Outcomes after Implantation of a New Hydrophobic Acrylic Toric IOL During Routine Cataract Surgery. *J Cataract Refract Surg* 2013;39:41-7.
247. Wolffsohn JS, Buckhurst PJ. Objective Analysis of Toric Intraocular Lens Rotation and Centration. *J Cataract Refract Surg* 2010;36:778-82.
248. Rampat R, Gatinel D. Multifocal and Extended Depth-of-Focus Intraocular Lenses in 2020. *Ophthalmology* 2021;128:e164-e85.

249. Berrow EJ, Wolffsohn JS, Bilkhu PS, Dhallu S. Visual Performance of a New Bi-Aspheric, Segmented, Asymmetric Multifocal Iol. *J Refract Surg* 2014;30:584-8.
250. Greene PR. Mechanical Considerations in Myopia: Relative Effects of Accommodation, Convergence, Intraocular Pressure, and the Extraocular Muscles. *American journal of optometry and physiological optics* 1980;57:902-14.
251. Trachtman JN, Giambalvo V, Feldman J. Biofeedback of Accommodation to Reduce Functional Myopia. *Biofeedback and self-regulation* 1981;6:547-62.
252. McCollim RJ. On the Nature of Myopia and the Mechanism of Accommodation. *Medical hypotheses* 1989;28:197-211.
253. Wolffsohn JS, Gilmartin B, Thomas R, Mallen EA. Refractive Error, Cognitive Demand and Nearwork-Induced Transient Myopia. *Curr Eye Res* 2003;27:363-70.
254. Wolffsohn JS, Gilmartin B, Li RW, et al. Nearwork-Induced Transient Myopia in Preadolescent Hong Kong Chinese. *Invest Ophthalmol Vis Sci* 2003;44:2284-9.
255. Gilmartin B, Mallen EA, Wolffsohn JS. Sympathetic Control of Accommodation: Evidence for Inter-Subject Variation. *Ophthalmic Physiol Opt* 2002;22:366-71.
256. Davies LN, Wolffsohn JS, Gilmartin B. Cognition, Ocular Accommodation, and Cardiovascular Function in Emmetropes and Late-Onset Myopes. *Invest Ophthalmol Vis Sci* 2005;46:1791-6.
257. Orr JB, Wolffsohn JS. We Are Being Myopic About Myopia Control. *Cont Lens Anterior Eye* 2016;39:85-7.
258. Wildsoet CF, Chia A, Cho P, et al. Imi - Interventions Myopia Institute: Interventions for Controlling Myopia Onset and Progression Report. *Invest Ophthalmol Vis Sci* 2019;60:M106-M31.
259. Lawrenson JG, Shah R, Huntjens B, et al. Interventions for Myopia Control in Children: A Living Systematic Review and Network Meta-Analysis. *The Cochrane database of systematic reviews* 2023;2:Cd014758.
260. Logan NS, Wolffsohn JS. Role of Un-Correction, under-Correction and over-Correction of Myopia as a Strategy for Slowing Myopic Progression. *Clin Exp Optom* 2020;103:133-7.
261. Tang SM, Zhang XJ, Wang YM, et al. Effect of Myopic Undercorrection on Habitual Reading Distance in Schoolchildren: The Hong Kong Children Eye Study. *Ophthalmol Ther* 2023;12:925-38.
262. Wolffsohn JS, Calossi A, Cho P, et al. Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice. *Cont Lens Anterior Eye* 2016;39:106-16.
263. Wolffsohn JS, Calossi A, Cho P, et al. Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice - 2019 Update. *Cont Lens Anterior Eye* 2020;43:9-17.
264. Wolffsohn JS, Whayeb Y, Logan NS, et al. Imi-Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice-2022 Update. *Invest Ophthalmol Vis Sci* 2023;64:6.
265. Nti AN, Owusu-Afriyie B, Osuagwu UL, et al. Trends in Myopia Management Attitudes and Strategies in Clinical Practice: Survey of Eye Care Practitioners in Africa. *Cont Lens Anterior Eye* 2023;46:101597.
266. Martinez-Perez C, Villa-Collar C, Santodomingo-Rubido J, Wolffsohn JS. Strategies and Attitudes on the Management of Myopia in Clinical Practice in Spain. *J Optom* 2023;16:64-73.
267. Buckhurst PJ, Wolffsohn JS, Shah S, et al. A New Optical Low Coherence Reflectometry Device for Ocular Biometry in Cataract Patients. *Br J Ophthalmol* 2009;93:949-53.
268. Santodomingo-Rubido J, Mallen EA, Gilmartin B, Wolffsohn JS. A New Non-Contact Optical Device for Ocular Biometry. *Br J Ophthalmol* 2002;86:458-62.
269. O'Donoghue L, Kapetanankis VV, McClelland JF, et al. Risk Factors for Childhood Myopia: Findings from the Nicer Study. *Invest Ophthalmol Vis Sci* 2015;56:1524-30.
270. McCullough SJ, O'Donoghue L, Saunders KJ. Six Year Refractive Change among White Children and Young Adults: Evidence for Significant Increase in Myopia among White UK Children. *PLoS One* 2016;11:e0146332.
271. McCullough S, Adamson G, Breslin KMM, et al. Axial Growth and Refractive Change in White European Children and Young Adults: Predictive Factors for Myopia. *Sci Rep* 2020;10:15189.

272. Logan NS, Shah P, Rudnicka AR, et al. Childhood Ethnic Differences in Ametropia and Ocular Biometry: The Aston Eye Study. *Ophthalmic Physiol Opt* 2011;31:550-8.
273. Wolffsohn JS, Kollbaum PS, Berntsen DA, et al. Imi - Clinical Myopia Control Trials and Instrumentation Report. *Invest Ophthalmol Vis Sci* 2019;60:M132-M60.
274. Logan NS, Radhakrishnan H, Cruickshank FE, et al. Imi Accommodation and Binocular Vision in Myopia Development and Progression. *Invest Ophthalmol Vis Sci* 2021;62:4.
275. Resnikoff S, Jonas JB, Friedman D, et al. Myopia - a 21st Century Public Health Issue. *Invest Ophthalmol Vis Sci* 2019;60:Mi-Mii.
276. Keel S, Govender-Poonsamy P, Cieza A, et al. The Who-Itu Myopiaed Programme: A Digital Message Programme Targeting Education on Myopia and Its Prevention. *Front Public Health* 2022;10:881889.
277. Jonas JB, Ang M, Cho P, et al. Imi Prevention of Myopia and Its Progression. *Invest Ophthalmol Vis Sci* 2021;62:6.
278. Nemeth J, Tapasztó B, Aclimandos WA, et al. Update and Guidance on Management of Myopia. European Society of Ophthalmology in Cooperation with International Myopia Institute. *Eur J Ophthalmol* 2021;31:853-83.
279. Wolffsohn JS, Jong M, Smith EL, 3rd, et al. Imi 2021 Reports and Digest - Reflections on the Implications for Clinical Practice. *Invest Ophthalmol Vis Sci* 2021;62:1.
280. Jong M, Jonas JB, Wolffsohn JS, et al. Imi 2021 Yearly Digest. *Invest Ophthalmol Vis Sci* 2021;62:7.
281. Sankaridurg P, Berntsen DA, Bullimore MA, et al. Imi 2023 Digest. *Invest Ophthalmol Vis Sci* 2023;64:7.
282. Craig JP, Nichols KK, Akpek EK, et al. Tfos Dews li Definition and Classification Report. *Ocul Surf* 2017;15:276-83.
283. Uchino M, Schaumberg DA. Dry Eye Disease: Impact on Quality of Life and Vision. *Current ophthalmology reports* 2013;1:51-7.
284. Clara C, Setareh Z, Varun M, et al. Economic Burden and Loss of Quality of Life from Dry Eye Disease in Canada. *BMJ Open Ophthalmol* 2021;6:e000709.
285. Li M, Gong L, Chapin WJ, Zhu M. Assessment of Vision-Related Quality of Life in Dry Eye Patients. *Invest Ophthalmol Vis Sci* 2012;53:5722-7.
286. Morthen MK, Magno MS, Utheim TP, et al. The Physical and Mental Burden of Dry Eye Disease: A Large Population-Based Study Investigating the Relationship with Health-Related Quality of Life and Its Determinants. *Ocul Surf* 2021;21:107-17.
287. An Y, Kim H. Sleep Disorders, Mental Health, and Dry Eye Disease in South Korea. *Sci Rep* 2022;12:11046.
288. Tounaka K, Yuki K, Kouyama K, et al. Dry Eye Disease Is Associated with Deterioration of Mental Health in Male Japanese University Staff. *The Tohoku journal of experimental medicine* 2014;233:215-20.
289. Stapleton F, Alves M, Bunya VY, et al. Tfos Dews li Epidemiology Report. *Ocul Surf* 2017;15:334-65.
290. Wolffsohn JS, Arita R, Chalmers R, et al. Tfos Dews li Diagnostic Methodology Report. *Ocul Surf* 2017;15:539-74.
291. Okumura Y, Inomata T, Iwata N, et al. A Review of Dry Eye Questionnaires: Measuring Patient-Reported Outcomes and Health-Related Quality of Life. *Diagnostics* 2020;10.
292. Wolffsohn JS. Chapter 1 - Questionnaire Design and Use to Assess Dry Eye Disease. In: Galor A, ed. *Dry Eye Disease*: Elsevier; 2023:1-14.
293. Pult H, Wolffsohn JS. The Development and Evaluation of the New Ocular Surface Disease Index-6. *Ocul Surf* 2019;17:817-21.
294. Bandlitz S, Peter B, Pflugl T, et al. Agreement and Repeatability of Four Different Devices to Measure Non-Invasive Tear Breakup Time (NIBUT). *Cont Lens Anterior Eye* 2020;43:507-11.

295. Downie LE. Automated Tear Film Surface Quality Breakup Time as a Novel Clinical Marker for Tear Hyperosmolarity in Dry Eye Disease. *Invest Ophthalmol Vis Sci* 2015;56:7260-8.
296. Santodomingo-Rubido J, Wolffsohn JS, Gilmartin B. Comparison between G-raticule and Image Capture Assessment of Lower Tear Film Meniscus Height. *Cont Lens Anterior Eye* 2006;29:169-73.
297. Niedernolte B, Trunk L, Wolffsohn JS, et al. Evaluation of Tear Meniscus Height Using Different Clinical Methods. *Clin Exp Optom* 2021;104:583-8.
298. Yang J, Zhu X, Liu Y, et al. Tmis: A New Image-Based Software Application for the Measurement of Tear Meniscus Height. *Acta Ophthalmol* 2019;97:e973-e80.
299. Arita R. Meibography: A Japanese Perspective. *Invest Ophthalmol Vis Sci* 2018;59:Des48-55.
300. Lee JS, Jun I, Kim EK, et al. Clinical Accuracy of an Advanced Corneal Topographer with Tear-Film Analysis in Functional and Structural Evaluation of Dry Eye Disease. *Seminars in ophthalmology* 2020;35:134-40.
301. Nagino K, Okumura Y, Yamaguchi M, et al. Diagnostic Ability of a Smartphone App for Dry Eye Disease: Protocol for a Multicenter, Open-Label, Prospective, and Cross-Sectional Study. *JMIR research protocols* 2023;12:e45218.
302. Uchino M, Kawashima M, Uchino Y, et al. The Evaluation of Dry Eye Mobile Apps for Screening of Dry Eye Disease and Educational Tear Event in Japan. *Ocul Surf* 2018;16:430-5.
303. Bandlitz S, Purslow C, Murphy PJ, et al. A New Portable Digital Meniscometer. *Optom Vis Sci* 2014;91:e1-8.
304. Wan C, Hua R, Guo P, et al. Measurement Method of Tear Meniscus Height Based on Deep Learning. *Front Med* 2023;10:1126754.
305. Wolffsohn JS, Craig JP, Vidal-Rohr M, et al. Blink Test Enhances Ability to Screen for Dry Eye Disease. *Cont Lens Anterior Eye* 2018;41:421-5.
306. Garcia-Marques JV, Talens-Estarellles C, Garcia-Lazaro S, et al. Systemic, Environmental and Lifestyle Risk Factors for Dry Eye Disease in a Mediterranean Caucasian Population. *Cont Lens Anterior Eye* 2022;45:101539.
307. Vidal-Rohr M, Craig JP, Davies LN, Wolffsohn JS. The Epidemiology of Dry Eye Disease in the UK: The Aston Dry Eye Study. *Cont Lens Anterior Eye* 2023;46:101837.
308. Wang MTM, Craig JP, Vidal-Rohr M, et al. Impact of Digital Screen Use and Lifestyle Factors on Dry Eye Disease in the Paediatric Population. *Ocul Surf* 2022;24:64-6.
309. Wang MTM, Muntz A, Mamidi B, et al. Modifiable Lifestyle Risk Factors for Dry Eye Disease. *Cont Lens Anterior Eye* 2021;44:101409.
310. Wang MTM, Vidal-Rohr M, Muntz A, et al. Systemic Risk Factors of Dry Eye Disease Subtypes: A New Zealand Cross-Sectional Study. *Ocul Surf* 2020;18:374-80.
311. Wolffsohn JS, Wang MTM, Vidal-Rohr M, et al. Demographic and Lifestyle Risk Factors of Dry Eye Disease Subtypes: A Cross-Sectional Study. *Ocul Surf* 2021;21:58-63.
312. Donthineni PR, Das AV, Basu S. Dry Eye Disease in Children and Adolescents in India. *Ocul Surf* 2020;18:777-82.
313. Rojas-Carabali W, Uribe-Reina P, Muñoz-Ortiz J, et al. High Prevalence of Abnormal Ocular Surface Tests in a Healthy Pediatric Population. *Clin Ophthalmol* 2020;14:3427-38.
314. Muntz A, Turnbull PR, Kim AD, et al. Extended Screen Time and Dry Eye in Youth. *Cont Lens Anterior Eye* 2022;45:101541.
315. Moore PA, Wolffsohn JS, Sheppard AL. Attitudes of Optometrists in the UK and Ireland to Digital Eye Strain and Approaches to Assessment and Management. *Ophthalmic Physiol Opt* 2021;41:1165-75.
316. Sheppard AL, Wolffsohn JS. Digital Eye Strain: Prevalence, Measurement and Amelioration. *BMJ Open Ophthalmol* 2018;3:e000146.
317. Wolffsohn JS, Lingham G, Downie LE, et al. Tfos Lifestyle: Impact of the Digital Environment on the Ocular Surface. *Ocul Surf* 2023;28:213-52.

318. Talens-Estarellles C, Cervino A, Garcia-Lazaro S, et al. The Effects of Breaks on Digital Eye Strain, Dry Eye and Binocular Vision: Testing the 20-20-20 Rule. *Cont Lens Anterior Eye* 2023;46:101744.
319. Alghamdi WM, Alrasheed SH. Impact of an Educational Intervention Using the 20/20/20 Rule on Computer Vision Syndrome. *African Vis Eye Health* 2020;79:554.
320. Johnson S, Rosenfield M. 20-20-20 Rule: Are These Numbers Justified? *Optom Vis Sci* 2023;100:52-6.
321. Kim AD, Muntz A, Lee J, et al. Therapeutic Benefits of Blinking Exercises in Dry Eye Disease. *Cont Lens Anterior Eye* 2021;44:101329.
322. Bilkhu P, Wolffsohn J, Purslow C. Provocation of the Ocular Surface to Investigate the Evaporative Pathophysiology of Dry Eye Disease. *Cont Lens Anterior Eye* 2021;44:24-9.
323. Bilkhu P, Vidal-Rohr M, Trave-Huarte S, Wolffsohn JS. Effect of Meibomian Gland Morphology on Functionality with Applied Treatment. *Cont Lens Anterior Eye* 2022;45:101402.
324. Wolffsohn JS, Tahhan M, Vidal-Rohr M, et al. Best Technique for Upper Lid Eversion. *Cont Lens Anterior Eye* 2019;42:666-9.
325. Steven LM, Whitney RT. Growth of Meibomian Gland Tissue after Intraductal Meibomian Gland Probing in Patients with Obstructive Meibomian Gland Dysfunction. *Br J Ophthalmol* 2018;102:59.
326. Bilkhu P, Sivardeen Z, Chen C, et al. Patient-Reported Experience of Dry Eye Management: An International Multicentre Survey. *Cont Lens Anterior Eye* 2022;45:101450.
327. Casemore RK, Wolffsohn JS, Dutta D. Dry Eye Clinical Practice Patterns of Uk Optometrists. *Cont Lens Anterior Eye* 2023;46:101889.
328. Semp DA, Beeson D, Sheppard AL, et al. Artificial Tears: A Systematic Review. *Clinical optometry* 2023;15:9-27.
329. Jones L, Downie LE, Korb D, et al. Tfos Dews li Management and Therapy Report. *Ocul Surf* 2017;15:575-628.
330. Craig JP, Muntz A, Wang MTM, et al. Developing Evidence-Based Guidance for the Treatment of Dry Eye Disease with Artificial Tear Supplements: A Six-Month Multicentre, Double-Masked Randomised Controlled Trial. *Ocul Surf* 2021;20:62-9.
331. Essa L, Laughton D, Wolffsohn JS. Can the Optimum Artificial Tear Treatment for Dry Eye Disease Be Predicted from Presenting Signs and Symptoms? *Cont Lens Anterior Eye* 2018;41:60-8.
332. Craig JP, Purslow C, Murphy PJ, Wolffsohn JS. Effect of a Liposomal Spray on the Pre-Ocular Tear Film. *Cont Lens Anterior Eye* 2010;33:83-7.
333. Pult H, Khatum FS, Trave-Huarte S, Wolffsohn JS. Effect of Eye Spray Phospholipid Concentration on the Tear Film and Ocular Comfort. *Eye Contact Lens* 2021;47:445-8.
334. Fong PY, Shih KC, Lam PY, et al. Role of Tear Film Biomarkers in the Diagnosis and Management of Dry Eye Disease. *Taiwan journal of ophthalmology* 2019;9:150-9.
335. Kumar NR, Praveen M, Narasimhan R, et al. Tear Biomarkers in Dry Eye Disease: Progress in the Last Decade. *Indian journal of ophthalmology* 2023;71:1190-202.
336. Mann A, Campbell D, Mirza Z, et al. Clinical and Biochemical Analysis of the Ageing Tear Film. *Br J Ophthalmol* 2020;104:1028-32.
337. Chiang JCB, Tran V, Wolffsohn JS. The Impact of Dry Eye Disease on Corneal Nerve Parameters: A Systematic Review and Meta-Analysis. *Ophthalmic Physiol Opt* 2023;43:1079-91.
338. Jia Z, Wei W, Tu K, et al. Point-of-Care Monitoring of Dry Eye Disease Using Lysozyme in Tear Based on Commercial Pregnancy Test Strips. *Sensors Actuators B: Chem* 2023;378:133179.
339. Zhang S, Echegoyen J. Point of Care Diagnosis of Dry Eye Disease with a Sensitive Immunoassay for Dual Biomarker Detection. *Biochemistry and biophysics reports* 2022;32:101396.
340. Bilkhu PS, Naroo SA, Wolffsohn JS. Effect of a Commercially Available Warm Compress on Eyelid Temperature and Tear Film in Healthy Eyes. *Optom Vis Sci* 2014;91:163-70.

341. Zhou X, Shen Y, Shang J, Zhou X. Effects of Warm Compress on Tear Film, Blink Pattern and Meibomian Gland Function in Dry Eyes after Corneal Refractive Surgery. *BMC Ophthalmology* 2021;21:330.
342. Schjerven Magno M, Olafsson J, Beining M, et al. Hot Towels: The Bedrock of Meibomian Gland Dysfunction Treatment - a Review. *Cont Lens Anterior Eye* 2023;46:101775.
343. Murphy O, V OD, Lloyd-Mckernan A. The Efficacy of Warm Compresses in the Treatment of Meibomian Gland Dysfunction and Demodex Folliculorum Blepharitis. *Curr Eye Res* 2020;45:563-75.
344. Bitton E, Lacroix Z, Léger S. In-Vivo Heat Retention Comparison of Eyelid Warming Masks. *Cont Lens Anterior Eye* 2016;39:311-5.
345. Borchman D. The Optimum Temperature for the Heat Therapy for Meibomian Gland Dysfunction. *Ocul Surf* 2019;17:360-4.
346. Hu J, Zhu S, Liu X. Efficacy and Safety of a Vectored Thermal Pulsation System (Lipiflow®) in the Treatment of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis. *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie* 2022;260:25-39.
347. Schanzlin D, Owen JP, Klein S, et al. Efficacy of the Systane Ilux Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction after 1 Week and 1 Month: A Prospective Study. *Eye Contact Lens* 2022;48:155-61.
348. Beining MW, Magnø MS, Moschowits E, et al. In-Office Thermal Systems for the Treatment of Dry Eye Disease. *Surv Ophthalmol* 2022;67:1405-18.
349. Trave-Huarte S, Wolffsohn JS. Efficacy of a Novel Water Propelled, Heating Eye Mask Massager on Tear Film and Ocular Adnexa. *Cont Lens Anterior Eye* 2021;44:101344.
350. Arita R, Morishige N, Shirakawa R, et al. Effects of Eyelid Warming Devices on Tear Film Parameters in Normal Subjects and Patients with Meibomian Gland Dysfunction. *Ocul Surf* 2015;13:321-30.
351. Sim HS, Petznick A, Barbier S, et al. A Randomized, Controlled Treatment Trial of Eyelid-Warming Therapies in Meibomian Gland Dysfunction. *Ophthalmol Ther* 2014;3:37-48.
352. Wolffsohn JS, Trave Huarte S, Jones L, et al. Clinical Practice Patterns in the Management of Dry Eye Disease: A Tfos International Survey. *Ocul Surf* 2021;21:78-86.
353. Cai Y, Wei J, Zhou J, Zou W. Prevalence and Incidence of Dry Eye Disease in Asia: A Systematic Review and Meta-Analysis. *Ophthal Res* 2022;65:647-58.
354. Wolffsohn JS, Naroo SA, Gupta N, Emberlin J. Prevalence and Impact of Ocular Allergy in the Population Attending Uk Optometric Practice. *Cont Lens Anterior Eye* 2011;34:133-8.
355. Villani E, Rabbio G, Nucci P. Ocular Allergy as a Risk Factor for Dry Eye in Adults and Children. *Current opinion in allergy and clinical immunology* 2018;18:398-403.
356. Bilkhu P, Wolffsohn JS, Taylor D, et al. The Management of Ocular Allergy in Community Pharmacies in the United Kingdom. *Int J Clin Pharm* 2013;35:190-4.
357. Bilkhu PS, Wolffsohn JS, Naroo SA. A Review of Non-Pharmacological and Pharmacological Management of Seasonal and Perennial Allergic Conjunctivitis. *Cont Lens Anterior Eye* 2012;35:9-16.
358. Bilkhu PS, Wolffsohn JS, Naroo SA, et al. Effectiveness of Nonpharmacologic Treatments for Acute Seasonal Allergic Conjunctivitis. *Ophthalmology* 2014;121:72-8.
359. Ono J, Toshida H. Use of Ketotifen Fumarate-Eluting Daily Disposable Soft Contact Lens in Management of Ocular Allergy: Literature Review and Report of Two Cases. *Cureus* 2022;14:e27093.